비교리스트

 카트 문의
시장보고서
상품코드
1671096

세계의 혈우병 A 치료 시장 규모, 점유율, 동향, 업계 분석 : 치료 유형별, 치료법 유형별, 유통 채널별, 지역별 - 예측(2025-2034년)

Hemophilia A Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, Therapy Type, Distribution Channel, and Region - Market Forecast, 2025-2034
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 116 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면 세계의 혈우병 A 치료 시장 규모는 2034년까지 198억 6,000만 달러에 달할 전망입니다. 이 조사 리포트는 현재 시장 역학에 대한 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.

혈우병 A 치료는 혈우병 A를 관리하고 치료하기 위한 의료적 개입을 의미합니다. 이 유전성 질환은 혈액 응고 제8인자가 충분하지 않아 혈액 응고가 어려워 과다 출혈의 위험이 높아지는 질환입니다. 혈우병 A의 주요 치료법은 유전자 재조합 또는 혈장 유래 혈액응고인자 보충요법을 통해 부족한 혈액응고인자를 보충하는 것입니다.

혈우병 A 치료제 시장은 유전자 치료, 반감기 연장 혈액응고 제8인자 제제, 에미시주맙과 같은 비응고인자 대체요법 등 치료 옵션의 발전으로 인해 성장하고 있습니다. 혈우병과 혈우병 관리에 대한 인식이 높아지고 의료 투자가 증가함에 따라 특히 신흥 시장에서 치료 접근성이 향상되고 있습니다.

유전적 근본 원인을 해결하고 피하주사와 같은 덜 침습적인 치료 옵션을 통해 환자의 순응도를 개선할 수 있는 혁신적인 치료법을 개발할 수 있는 기회가 존재합니다. 주목할 만한 동향은 투여 횟수를 줄일 수 있는 반감기 연장형 제8인자 제제의 개발입니다. 또한 비인자 보충제 및 유전자 편집 기술 등 혁신적인 치료법에 대한 막대한 투자가 시장 상황을 형성하고 있습니다.

혈우병 A 치료제 시장 : 분석 개요

치료 유형별로는 출혈 에피소드를 예방하고 환자의 삶의 질을 향상시키는 예방요법이 혈우병 A 치료 시장에서 가장 큰 비중을 차지하고 있습니다. 특히 젊은 환자들을 중심으로 장기적인 관리로 점점 더 많은 지지를 받고 있습니다.

치료법 유형별로는 제8인자 제제가 온디맨드 치료 및 예방에 널리 사용되고 있으며, 유전자 재조합 요법과 혈장 유래 제8인자 제제가 시장을 주도하고 있습니다. 유전자 치료와 단클론 항체는 가장 빠르게 성장하고 있는 분야로, 장기적인 해결책을 제공할 수 있는 잠재력을 가지고 있습니다.

병원약국은 급성기 치료와 응급치료에서 중요한 역할을 담당하고 있으므로 지배적인 유통 채널로 자리 잡고 있습니다. 전문약국은 특히 유전자치료제나 모노클로널 항체와 같은 첨단 치료제의 경우 가장 빠른 성장세를 보이고 있습니다.

북미는 잘 구축된 의료 인프라와 높은 혁신적 치료법 도입률에 힘입어 가장 큰 시장 점유율을 차지하고 있습니다. 아시아태평양은 의료 접근성 확대, 환자 인식 개선, 신흥 경제권의 투자 증가 등을 배경으로 빠르게 성장하고 있습니다.

목차

제1장 서론

제2장 개요

제3장 분석 방법

제4장 혈우병 A 치료 시장 인사이트

  • 시장 스냅숏
  • 혈우병 A 치료 시장 역학
    • 촉진요인과 기회
      • 유전자 치료의 진보
      • 반감기 연장 제품의 채택
      • 비인자 보충 요법의 부상
    • 억제요인과 과제
      • 치료비의 상승
  • PESTLE 분석
  • 혈우병 A 치료 시장 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 혈우병 A 치료 시장 : 치료 유형별

  • 주요 조사 결과
  • 서론
  • 온디맨드
  • 치료
  • 예방

제6장 세계의 혈우병 A 치료 시장 : 치료법 유형별

  • 주요 조사 결과
  • 서론
  • 인자 보충 요법
  • 데스모프레신·피브린 실란트
  • 유전자 치료·모노클로널 항체

제7장 세계의 혈우병 A 치료 시장 : 유통 채널별

  • 주요 조사 결과
  • 서론
  • 병원 약국
  • 전문 약국

제8장 세계의 혈우병 A 치료 시장 : 지역별

  • 주요 분석 결과
  • 서론
    • 혈우병 A 치료 시장 평가 : 지역별(2020-2034년)
  • 북미
    • 북미 : 치료 유형별(2020-2034년)
    • 북미 : 치료법 유형별(2020-2034년)
    • 북미 : 유통 채널별(2020-2034년)
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 치료 유형별(2020-2034년)
    • 유럽 : 치료법 유형별(2020-2034년)
    • 유럽 : 유통 채널별(2020-2034년)
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 치료 유형별(2020-2034년)
    • 아시아태평양 : 치료법 유형별(2020-2034년)
    • 아시아태평양 : 유통 채널별(2020-2034년)
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 치료 유형별(2020-2034년)
    • 중동 및 아프리카 : 치료법 유형별(2020-2034년)
    • 중동 및 아프리카 : 유통 채널별(2020-2034년)
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 남아프리카공화국
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 치료 유형별(2020-2034년)
    • 라틴아메리카 : 치료법 유형별(2020-2034년)
    • 라틴아메리카 : 유통 채널별(2020-2034년)
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제9장 경쟁 구도

  • 확대와 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제10장 기업 개요

  • CSL Behring
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Sanofi(through its acquisition of Bioverativ)
  • F. Hoffmann-La Roche Ltd.
  • Octapharma AG
  • Grifols S.A.
  • BioMarin Pharmaceutical Inc.
  • Spark Therapeutics(a subsidiary of Roche)
  • Aptevo Therapeutics
  • Kedrion Biopharma
  • Sangamo Therapeutics
  • uniQure N.V.
KSA 25.03.27

The global hemophilia A treatment market size is expected to reach USD 19.86 billion by 2034, according to a new study by Polaris Market Research. The report "Hemophilia A Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (On-Demand, Cure, and Prophylaxis), Therapy Type, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Hemophilia A treatment refers to the medical interventions used to manage and treat hemophilia A. In this genetic disorder, the blood lacks sufficient clotting factor VIII, leading to difficulty in blood clotting and an increased risk of excessive bleeding. The primary treatment for Hemophilia A involves replacing the missing clotting factor through factor replacement therapy, which can be either recombinant or plasma-derived.

The hemophilia A treatment market is driven by advancements in therapeutic options, including gene therapy, extended half-life factor VIII products, and non-factor replacement therapies like emicizumab. Growing awareness about hemophilia and its management, along with increasing healthcare investments, is enhancing access to treatments, particularly in emerging markets.

Opportunities exist in developing innovative therapies that address the genetic root causes and improve patient compliance through less invasive treatment options such as subcutaneous injections. A notable trend is the development of extended half-life factor VIII products, offering reduced dosing frequency. Additionally, significant investments in innovative therapies, including non-factor replacement products and gene-editing technologies, are shaping the market landscape.

Hemophilia A Treatment Market Report Highlights

Based on treatment type, prophylaxis holds the largest share in the hemophilia A treatment market due to its ability to prevent bleeding episodes and improve patient quality of life. It is increasingly favored for long-term management, particularly among younger patients.

By therapy type, the factor replacement therapy segment dominates the market, with recombinant and plasma-derived factor VIII products being widely used for on-demand treatment and prophylaxis. Gene therapy & monoclonal antibodies is the fastest-growing segment, offering potential long-term solutions.

Hospital pharmacies are the dominant distribution channel due to their critical role in acute care and emergency treatment. Specialty pharmacies are registering the fastest growth, particularly for advanced therapies like gene therapy and monoclonal antibodies.

North America holds the largest market share, driven by a well-established healthcare infrastructure and high adoption of innovative therapies. Asia Pacific is the fastest-growing region, fueled by expanding healthcare access, rising patient awareness, and increasing investments in emerging economies.

Polaris Market Research has segmented the hemophilia A treatment market report on the basis of treatment type, therapy type, distribution channnel, and region:

By Treatment Type Outlook (Revenue - USD Billion, 2020-2034)

  • On-Demand
  • Cure
  • Prophylaxis

By Therapy Type Outlook (Revenue - USD Billion, 2020-2034)

  • Factor Replacement Therapy
  • Desmopressin & Fibrin Sealants
  • Gene Therapy & Monoclonal Antibodies

By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)

  • Hospital Pharmacies
  • Specialty Pharmacies

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Source
    • 3.2.1. Primary Source
    • 3.2.2. Secondary Source

4. Global Hemophilia A Treatment Market Insights

  • 4.1. Hemophilia A Treatment Market - Market Snapshot
  • 4.2. Hemophilia A Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Advancements in Gene Therapy
      • 4.2.1.2. Adoption of Extended Half-Life Products
      • 4.2.1.3. Rise of Non-Factor Replacement Therapies
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Treatments
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Hemophilia A Treatment Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Hemophilia A Treatment Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • 5.3. On-Demand
    • 5.3.1. Global Hemophilia A Treatment Market, by On-Demand, by Region, 2020-2034 (USD Billion)
  • 5.4. Cure
    • 5.4.1. Global Hemophilia A Treatment Market, by Cure, by Region, 2020-2034 (USD Billion)
  • 5.5. Prophylaxis
    • 5.5.1. Global Hemophilia A Treatment Market, by Prophylaxis, by Region, 2020-2034 (USD Billion)

6. Global Hemophilia A Treatment Market, by Therapy Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • 6.3. Factor Replacement Therapy
    • 6.3.1. Global Hemophilia A Treatment Market, by Factor Replacement Therapy, by Region, 2020-2034 (USD Billion)
  • 6.4. Desmopressin & Fibrin Sealants
    • 6.4.1. Global Hemophilia A Treatment Market, by Desmopressin & Fibrin Sealants, by Region, 2020-2034 (USD Billion)
  • 6.5. Gene Therapy & Monoclonal Antibodies
    • 6.5.1. Global Hemophilia A Treatment Market, by Gene Therapy & Monoclonal Antibodies, by Region, 2020-2034 (USD Billion)

7. Global Hemophilia A Treatment Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Hemophilia A Treatment Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
  • 7.4. Specialty Pharmacies
    • 7.4.1. Global Hemophilia A Treatment Market, by Specialty Pharmacies, by Region, 2020-2034 (USD Billion)

8. Global Hemophilia A Treatment Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Hemophilia A Treatment Market Assessment, b y Geography, 2020-2034 (USD Billion)
  • 8.3. Hemophilia A Treatment Market - North America
    • 8.3.1. North America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.3.2. North America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.3.3. North America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.4. Hemophilia A Treatment Market - US
      • 8.3.4.1. US: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.3.4.2. US : Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.3.4.3. US : Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.5. Hemophilia A Treatment Market - Canada
      • 8.3.5.1. Canada: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4. Hemophilia A Treatment Market - Europe
    • 8.4.1. Europe: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.4. Hemophilia A Treatment Market - UK
      • 8.4.4.1. UK: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.5. Hemophilia A Treatment Market - France
      • 8.4.5.1. France: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.6. Hemophilia A Treatment Market - Germany
      • 8.4.6.1. Germany: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.7. Hemophilia A Treatment Market - Italy
      • 8.4.7.1. Italy: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.8. Hemophilia A Treatment Market - Spain
      • 8.4.8.1. Spain: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.9. Hemophilia A Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.10. Hemophilia A Treatment Market - Russia
      • 8.4.10.1. Russia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.11. Hemophilia A Treatment Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5. Hemophilia A Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.4. Hemophilia A Treatment Market - China
      • 8.5.4.1. China: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.5. Hemophilia A Treatment Market - India
      • 8.5.5.1. India: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.6. Hemophilia A Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.7. Hemophilia A Treatment Market - Japan
      • 8.5.7.1. Japan: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.8. Hemophilia A Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.9. Hemophilia A Treatment Market - South Korea
      • 8.5.9.1. South Korea: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.10. Hemophilia A Treatment Market - Australia
      • 8.5.10.1. Australia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.11. Hemophilia A Treatment Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6. Hemophilia A Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.4. Hemophilia A Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.5. Hemophilia A Treatment Market - UAE
      • 8.6.5.1. UAE: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.6. Hemophilia A Treatment Market - Israel
      • 8.6.6.1. Israel: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.7. Hemophilia A Treatment Market - South Africa
      • 8.6.7.1. South Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.8. Hemophilia A Treatment Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.7. Hemophilia A Treatment Market - Latin America
    • 8.7.1. Latin America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.4. Hemophilia A Treatment Market - Mexico
      • 8.7.4.1. Mexico: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.5. Hemophilia A Treatment Market - Brazil
      • 8.7.5.1. Brazil: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.6. Hemophilia A Treatment Market - Argentina
      • 8.7.6.1. Argentina: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.7. Hemophilia A Treatment Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. CSL Behring
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Pfizer Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Novo Nordisk A/S
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Takeda Pharmaceutical Company Limited
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Bayer AG
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Sanofi (through its acquisition of Bioverativ)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. F. Hoffmann-La Roche Ltd.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Octapharma AG
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Grifols S.A.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. BioMarin Pharmaceutical Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Spark Therapeutics (a subsidiary of Roche)
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Aptevo Therapeutics
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Kedrion Biopharma
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Sangamo Therapeutics
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. uniQure N.V.
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제